Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
Primary Industries
- Wound Care
- Medical
- Surgical
- Drugs
- Supply
- Therapeutic
- Pharmaceuticals
- Dermatology
- Biotechnology
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 383121
License Grant
Buyer will purchase all wholly owned Sellers assets related to wound-care which are Amniobind, next generation Amniobind, and injectable regenerative medicine products only to the extent these are indicated for wound care; as well as wholly owned Seller IP, IT and equipment for producing Amniobind and next generation Amniobind and injectable regenerative medicine products only to the extent these are indicated for wound care – (collectively the Wound Care Assets).
Buyer will non-exclusively license, sublicense, lease, or sublease equipment that is not owned by Seller but is used for the production of Wound Care Assets.
Field of Use
Field of use is for wound-care.
IPSCIO Record ID: 304408
License Grant
The Company has an exclusive sublicense to distribute CellerateRX® Activated Collagen® products into the wound care and surgical markets in the United States, Canada and Mexico.
License Property
CellerateRX® is a wound and skin care product for use by surgeons on surgical wounds consisting of a Surgical Powder that is a medical hydrolysate of Type I bovine collagen. When applied to a surgical wound, the hydrolyzed collagen is ready to aid in the natural wound healing process.
Licensor manufactures the products and owns the CellerateRX registered trademark.
Field of Use
CellerateRX Surgical Powder is a medical hydrolysate of Type I bovine collagen indicated for the management of
Surgical wounds
Traumatic wounds
Partial- and full-thickness wounds
First- and second-degree burns
Licensee will utilize the wound and skin care products for external wounds, including the treatment of external, tunneled or undermined wounds. These products are used by surgeons in the medical industry. This would include pressure ulcers (Stages I-IV), venous stasis ulcers, diabetic ulcers, ulcers resulting from arterial insufficiency, surgical wounds, traumatic wounds, first and second-degree burns, superficial wounds, cuts, scrapes, skin tears, skin flaps and skin grafts.
The Licensees business is developing, marketing, and distributing wound and skin care products to physicians, hospitals, clinics and post-acute care settings.
IPSCIO Record ID: 614
License Grant
The Licensors grants the Licensee a non-revocable, exclusive, sub-licensable, transferable right in and to the Licensed IP to make, have made, use, sell, export, reproduce, market and distribute Products for External Wound Care in the field of use.
License Property
External Wound Care means the treatment of external, tunneled or undermined wounds (including, without limitation, pressure ulcers (Stages I – IV), venous stasis ulcers, diabetic ulcers, ulcers resulting from arterial insufficiency, surgical wounds, traumatic wounds, first and second degree burns, superficial wounds, cuts scrapes, skin tears, skin flaps and skin grafts.
Patent means – United States Patent No. 6,136,341.
The patented technologies and processes related to CellerateRxTM, an advanced collagen based wound care product formulation. These new licenses are limited to the human health care market for external wound care, and include any new product developments based on the licensed patent and processes.
Field of Use
The Field of Use means the worldwide human health care market, (excluding the veterinary, nutritional and injectable markets as well as all other uses) and subject to certain exceptions.
IPSCIO Record ID: 237112
License Grant
The Licensor shall grant to the Japanese Licensee an exclusive license, with limited right to sublicense, to use Licensor Technology for manufacturing, or having third-party manufacture devices which are covered by the Licensor Patent or embodied by Licensor Know How, such as the New Devices and Centrifuge of current and future version, for the Territory. for all wound care and topical dermatology applications of the Companys Aurix® system and related intellectual property and know-how in human and veterinary medicine in Japan.
License Property
The Licensors intellectual property is for wound care and topical dermatology applications of the Licensors Aurix® system and related intellectual property and know-how in human and veterinary medicine in Japan.
The Aurix® System is used at point-of-care for the safe and rapid preparation of biodynamic hematogel from a small sample of a patient’s own blood.
Field of Use
Wound care solutions in humans and animals.
IPSCIO Record ID: 26365
License Grant
The Licensee entered into an agreement with a national blood bank, under which the blood bank supplies the blood that serves as the raw material for, and manufactures, the Licensee's CureXcell product in Israel. Under the agreement, the blood bank produces CureXcell based on the Licensed Technology and based on the Licensee’s needs.
License Property
CureXcell is an injectable suspension of living human white blood cells, including macrophages, neutrophils and lymphocytes, that are crucial to initiating, promoting and completing the process of cellular regeneration and wound healing. The Licensee uses proprietary cell activation technology to trigger these cells to release growth factors and other biochemical factors that improve the healing environment in the wound bed and stimulate wound closure.
Field of Use
The CureXcell product is sold to health care professionals in Israel for clinical purposes as part of the Licensee’s research and development activities. The Licensee is a regenerative medicine company focused on developing, manufacturing and commercializing novel cell therapy products to address unmet needs in the treatment of chronic and other hard-to-heal wounds. Their product candidate, CureXcell, is an advanced wound care, or AWC, therapy to treat such wounds by injecting living human white blood cells that have been activated to facilitate the healing process. CureXcell is currently in two pivotal, Phase 3, double-blind clinical trials targeting a broad indication for the treatment of diabetic foot ulcers, or DFUs, and venous leg ulcers, or VLUs. The Licensee anticipates results from their DFU clinical trial and interim data from their VLU clinical trial in the second half of 2015. They already hold product approval for CureXcell as a medical device in Israel for the treatment of chronic and other hard-to-heal wounds, and have effectively and safely treated more than 5,000 patients in commercial or clinical study settings in Israel.
IPSCIO Record ID: 287103
License Grant
The Company consummated definitive agreements that continued operations to market the Company’s principal products, CellerateRX® Surgical Activated Collagen® Peptides and CellerateRX® Hydrolyzed Collagen wound fillers (CellerateRX), through a 50% ownership interest in a newly formed Texas limited liability company, which began operations on September 1, 2018.
The Companys affiliate conducts operations with an exclusive sublicense from the Licensors affiliate to distribute Licensees products into the wound care and surgical markets in the United States, Canada and Mexico.
License Property
The Companys products are primarily purchased by hospitals and ambulatory surgical centers for use by surgeons on surgical wounds.
CellerateRX® Gel is a hydrolyzed collagen wound dressing (approximately 65% type I collagen).
Field of Use
CellerateRX® products are primarily purchased by hospitals and ambulatory surgical centers for use by surgeons on surgical wounds.
The Company’s business is developing, marketing, and distributing wound and skin care products to physicians, hospitals, clinics and post-acute care settings.
IPSCIO Record ID: 256319
License Grant
The University grants a worldwide right and license to make, have made, use, lease, sell, and sublicense the Pre-issuance Products and Licensed Products under the Patent Rights, and to practice and sublicense the Pre-issuance Processes and Licensed Processes to the full end of the term(s) for which Patent Rights are granted unless sooner terminated as hereinafter provided.
License Property
The Invention will mean a wound treatment technology, Method and Apparatus to Enhance Closure and Health of Open Wounds.
The patents are Wound Dressing and Treatment Method, Fluidic Connection System and Method, and, Fastening System and Method.
Field of Use
Licensee is a global medical technology company in advanced wound care and therapeutic surfaces.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
